Dr. Gianni Colotti, Ph.D.
Primo Ricercatore
Istituto di Biologia e Patologia Molecolari IBPM CNR
P.le A. Moro 5, 00185 Roma
ESPERIENZA LAVORATIVA
Dal 2020: Primo Ricercatore CNR
2017: Abilitazione Scientifica Nazionale a Professore Universitario, I fascia, Settore Concorsuale 05/E1 – Biochimica
1996-2020: Ricercatore, IBPM-CNR (Consiglio Nazionale delle Ricerche).
1994-1995: Post-doc Scienze Mediche, Università Sapienza di Roma.
1993-1994: CNR fellowship in Biologia Molecolare e Biotecnlogia
1991-1993: Program in Molecular Medicine and Department of Biochemistry and Molecular Biology, University of Massachusetts Medical Center, Worcester, Massachusetts.
1990-1993: Dottorato di Ricerca in Biochimica, Università Sapienza, Roma
STUDI
1989: laurea in Scienze Biologiche (con lode), Università Sapienza, Roma.
1993: Ph.D. in Biochimica, Università Sapienza, Roma
ATTIVITA'
dal 2020: Membro del Consiglio d’Istituto, IBPM CNR
2018-2019: Membro del Consiglio Direttivo della Società Italiana Vescicole Extracellulari (EVIta).
dal 2018: Membro di NeuroNet, network CNR sulle Neuroscienze.
dal 2017: Membro dell’European Huntington’s Disease Network.
dal 2016: Cofondatore di Thena Biotech.
dal 2016: membro SIB (Italian Society of Biochemistry).
dal 2013: Membro di LeishRIIP, Institute Pasteur, per la ricerca sulla leishmaniasi.
dal 2012: Cofondatore di qPMO (Quality and Project Management OpenLab) CNR.
dal 2011: Membro del consiglio scientifico della Biocrystal Facility CNR.
2011-oggi: Cofondatore e membro della Biocrystal Facility CNR.
dal 2012: Cofondatore e membro del Foresight Group CNR.
2010-2015: Coordinatore per il trasferimento tecnologico IBPM CNR.
INSEGNAMENTO
dal 2017: Membro del Collegio dei Docenti della Scuola di Dottorato di Ricerca in Biochimica dell’Università Sapienza.
2011: Corso "Bioinformatics for biology", Univ. L'Aquila, Italy
2010: Corso "Bioinformatics for Molecular Biologists", CNR.
2007: Corso "Bioinformatics for Biologists", CNR.
2005: Corso "Applications of Bioinformatics in Molecular and Structural Biology” CNR.
2005: Corso "Bioinformatics for Molecular Biologists", Ph.D. in Cellular Biology, Roma.
1997-2010: Corso di Biologia Molecolare, Scuola di Specializzazione in Anatomia Patologica, Facoltà di Medicina e Chirurgia, Univ. Sapienza, Roma.
1997-2008: Corso di Biologia Molecolare, 1° Scuola di Specializzazione in Oncologia, Facoltà di Medicina e Chirurgia, Univ. Sapienza, Roma.
Membro dell’Editorial Board delle riviste: Scientific Reports; Mini Reviews in Medicinal Chemistry; Frontiers in Microbiology; Frontiers in Molecular Biosciences; Frontiers in Cell and Developmental Biology; ISRN Structural Biology.
Reviewer per National Science Foundation, European FP7, Israel Science Foundation, Austrian Science Foundation, MRC Cambridge, Agence Nationale de la Recherche France (ANR), Joint Projects Università Verona, Czech Health Research Council.
Invited speaker :15 invited lectures in meeting internazionali negli ultimi 7 anni).
RESPONSABILITA' DI RICERCA:
2023-2025: Coordinatore Scientifico di Unità Operativa UO2, Progetto PRIN: PROGETTI DI RICERCA DI RILEVANTE INTERESSE NAZIONALE – Bando 2022, Prot. 2022HYF8KS.
Tryp4Leish: a One Health approach for the structure-based discovery of anti-leishmania agents interfering with the trypanothione-based defense system in trypanosomatids - Tryp4Leish: un approccio One Health per la progettazione "structure-based" di nuovi agenti anti-leishmania in grado di interferire con il sistema di difesa basato sul tripanotione caratteristico dei tripanosomatidi
2018-2022: Italian Substitute, COST (European Cooperation in Science and Technology) Harmonising standardisation strategies to increase efficiency and competitiveness of European life-science research (CHARME), WG4, WG5.
2013-2019: Coordinatore di Work Package (WP2): Flagship Project Nanomax: NADINE “Nanotechnology-based Diagnostics In Neurological diseases and Experimental oncology”
2012-2017. Coordinatore Scientifico di Unità Operativa, Progetto: “Pemphigus vulgaris as a paradigm of autoantibody-mediated organ-specific autoimmune disorder: pathophysiology and novel tools for diagnosis and therapy” Ricerca finalizzata 2010, Min. Salute. Progetto RF-2010-2309790.
2012-2015. Coordinatore Scientifico di Unità Operativa: “Quality methods for Design of Experiments in Scientific Research”, in the Framework of the FaReBio di Qualità Project: Quality and Project Management OpenLab: qPMO CNR. Prot. IEOS – CNR N. 0000623 del 24/4/2013.
2010-2012: Coordinatore di progetto: “Molecular complexes of sorcin and E-Syt1 in the generation and regulation of calcium-dependent cellular functions”, CNR-CSIC.
2008-2011: Coordinatore Scientifico di Unità Operativa, PRIN (Research Programs of National Interest) 2007 “Supramolecular complexes of sorcin in the generation and regulation of Calcium-dependent cellular functions”.
PUBBLICAZIONI
102 pubblicazioni peer reviewed in riviste internazionali, 5 capitoli di libro.
H-index: 38: Google Scholar; 33: Scopus.
SELECTED PUBLICATIONS (last 6 years) (*: corresponding author)
1. Saccoliti F, Angiulli G, Pupo G, Pescatori L, Madia VN, Messore A, Colotti G, Fiorillo A, Scipione L, Gramiccia M, Di Muccio T, Di Santo R, Costi R, Ilari A.
“Inhibition of Leishmania infantum trypanothione reductase by diaryl sulfide derivatives”.
J Enzyme Inhib Med Chem. 2017; 32(1):304-310.
2. Ilari A, Fiorillo A, Genovese I, Colotti G*.
Polyamine-trypanothione pathway: an update.
Future Med Chem. 2017 Jan; 9(1):61-77.
3. Poser E, Genovese I, Masciarelli S, Bellissimo T, Fazi F, Colotti G*.
Surface Plasmon Resonance: A Useful Strategy for the Identification of Small Molecule Argonaute 2 Protein Binders.
Methods Mol Biol. 2017; 1517:223-237.
4. Bellissimo T, Masciarelli S, Poser E, Genovese I, Del Rio A, Colotti G, Fazi F.
“Small Molecules Targeting the miRNA-Binding Domain of Argonaute 2: From Computer-Aided Molecular Design to RNA Immunoprecipitation”.
Methods Mol Biol. 2017; 1517:211-221.
5. Mosca L, Falvo E, Ceci P, Poser E, Genovese I, Guarguaglini G, Colotti G*
“Use of Ferritin-Based Metal-Encapsulated Nanocarriers as Anticancer Agents”
Applied Sciences 2017, 7, 101. doi:10.3390/app7010101
6. Morea V, Bidollari E, Colotti G, Fiorillo A, Rosati J, De Filippis L, Squitieri F, Ilari A.
"Glucose transportation in the brain and its impairment in Huntington disease: one more shade of the energetic metabolism failure?”
Amino Acids. 2017, 49, 7, 1147-1157. doi: 10.1007/s00726-017-2417-2.
7: Asteriti IA, Daidone F, Colotti G, Rinaldo S, Lavia P, Guarguaglini G, Paiardini A.
“Identification of small molecule inhibitors of the Aurora-A/TPX2 complex.”
Oncotarget. 2017 Mar 31. doi: 10.18632/oncotarget.16738.
8: Genovese I, Fiorillo A, Ilari A, Masciarelli S, Fazi F, Colotti G*.
“Binding of doxorubicin to Sorcin impairs cell death and increases drug resistance in cancer cells.”
Cell Death and Disease. 2017. 8, 7, e2950. doi: 10.1038/cddis.2017.342.
9. Genovese I, Ilari A, Assaraf YG, Fazi F, Colotti G*.
“Not only P-glycoprotein: amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins.”
Drug Resistance Updates. 2017, 32, 23-46. doi: 10.1016/j.drup.2017.10.003
10: Ferrara M, Sessa G, Fiore M, Bernard F, Asteriti IA, Cundari E, Colotti G, Ferla S, Desideri M, Buglioni D, Triscuoglio D, Del Bufalo D, Brancale A, Degrassi F.
“Small molecules targeted to the microtubule-Hec1 interaction inhibit cancer cell growth through microtubule stabilization”
Oncogene. 2018, 37(2):231-240. doi: 10.1038/onc.2017.320.
11: Colotti G*, Fiorillo A, Ilari A.
“Metal-and metalloid-containing drugs for the treatment of trypanosomatid diseases.”
Frontiers in biosciences. 2018. 23, 954-966. doi: 10.2741/4628.
12: De Cola A, Franceschini M, Di Matteo A, Colotti G, Celani R, Clemente E, Ippoliti R, Cimini AM, Dhez AC, Vallée B, Raineri F, Cascone I, Destouches D, De Laurenzi V, Courty J, Federici L.
“N6L pseudopeptide interferes with nucleophosmin protein-protein interactions and sensitizes leukemic cells to chemotherapy.”
Cancer Letters. 2018, 412, 272-282. doi: 10.1016/j.canlet.2017.10.038
13: Falvo E, Malagrinò F, Arcovito A, Fazi F, Colotti G, Tremante E, Di Micco P, Braca A, Opri R, Giuffrè A, Fracasso G, Ceci P.
“The presence of glutamate residues on the PAS sequence of the stimuli-sensitive nano-ferritin improves in vivo biodistribution and mitoxantrone encapsulation homogeneity.”
J Control Release. 2018 Feb 20;275:177-185. doi: 10.1016/j.jconrel.2018.02.025.
14: Ortalli M, Ilari A, Colotti G, De Ionna I, Battista T, Bisi A, Gobbi S, Rampa A, Di Martino RMC, Gentilomi GA, Varani S, Belluti F
“Identification of chalcone-based antileishmanial agents targeting trypanothione reductase”
European journal of medicinal chemistry 152, 527-541. doi: 10.1016/j.ejmech.2018.04.057.
15. Ilari A, Genovese I, Fiorillo F, Battista T, De Ionna I, Fiorillo A, Colotti G*.
“Toward a Drug Against All Kinetoplastids: From LeishBox to Specific and Potent Trypanothione Reductase Inhibitors.”
Mol Pharm. 2018 Jun 27. doi: 10.1021/acs.molpharmaceut.8b00185.
16. Genovese I, Ilari A, Battista T, Chiarini V, Fazi F, Fiorillo A, Colotti G.*
“Molecular bases of Sorcin-dependent resistance to chemotherapeutic agents”
Cancer Drug Resist. 2018; 1:164-180. doi:10.20517/cdr.2018.10.
17. Kahremany S, Zhenin M, Shenberger Y, Maimoun D, Colotti G, Arad M, Shainberg A, Senderowitz H, Ruthstein S, Gruzman A.
“Peptide-based development of PKA inhibitors”
New Journal of Chemistry 2018, 42, 23:18585-18597. doi: 10.1039/C8NJ01732H.
18. Turcano L, Torrente E, Missineo A, Andreini M, Gramiccia M, Di Muccio T, Genovese I, Fiorillo A, Harper S, Bresciani A, Colotti G*, Ilari A.
“Identification and binding mode of a novel Leishmania Trypanothione reductase inhibitor from high throughput screening”
PLOS Neglected Tropical Diseases 2018, 12,11:e0006969. doi:10.1371/journal.pntd.0006969
19. Pippa S, Mannironi C, Licursi V, Bombardi L, Colotti G, Cundari E, Mollica A, Coluccia A, Naccarato V, La Regina G, Silvestri R, Negri R.
“Small Molecule Inhibitors of KDM5 Histone Demethylases Increase the Radiosensitivity of Breast Cancer Cells Overexpressing JARID1B”
Molecules 2019, 1, 9:1739. doi:10.3390/molecules24091739.
20. Chiarini V, Tossavainen H, Sharma V, Colotti G*.
“NMR structure of a non-conjugatable, ADP-ribosylation associated, ubiquitin-like domain from Tetrahymena thermophila polyubiquitin locus”
Biochimica et Biophysica Acta (BBA)-General Subjects 2019, 1863, 4:749. doi: 10.1016/j.bbagen.2019.01.014.
21. Colotti G*, Saccoliti F, Gramiccia M, Di Muccio T, Prakash J, Yadav S, Kumar Dubey V, Vistoli G, Battista T, Mocci S, Fiorillo A, Bibi A, Madia VN, Messore A, Costi R, Di Santo R, Ilari A.
“Structure-guided approach to identify a novel class of anti-leishmaniasis diaryl sulfide compounds targeting the trypanothione metabolism”
Amino Acids 2019, 1-13. doi: 10.1007/s00726-019-02731-4.
22. Rinaldi T, Colotti G*.
“Use of organoids in medicinal chemistry: challenges on ethics and biosecurity”
Future Medicinal Chemistry 2019, 11 (10), 1087-1090. doi: 10.4155/fmc-2018-0341.
23. Carbo M, Brandi V, Pascarella G, Staid DS, Colotti G, Polticelli F, Ilari A, Morea V.
“Bioinformatics analysis of Ras homologue enriched in the striatum, a potential target for Huntington's disease therapy”
International journal of molecular medicine 2019, 4373. doi: 10.3892/ijmm.2019.4373.
24. Battista T, Fiorillo A, Chiarini V, Genovese I, Ilari A, Colotti G*.
“Roles of Sorcin in Drug Resistance in Cancer: One Protein, Many Mechanisms, for a Novel Potential Anticancer Drug Target.
Cancers (Basel). 2020 Apr 6;12(4):887. doi: 10.3390/cancers12040887.
25. Caroselli S, Zwergel C, Pirolli A, Sabatino M, Xu Z, Kirsch G, Mai A, Colotti G, Altieri F, Canipari R, Valente S, Ragno R.
“Discovery of the First Human Arylsulfatase A Reversible Inhibitor Impairing Mouse Oocyte Fertilization”.
ACS Chem Biol. 2020 Jun 19;15(6):1349-1357. doi: 10.1021/acschembio.9b00999.
26. Genovese I, Carotti A, Ilari A, Fiorillo A, Battista T, Colotti G, Ivarsson Y.
“Profiling calcium-dependent interactions between Sorcin and intrinsically disordered regions of human proteome.
Biochim Biophys Acta Gen Subj. 2020 Aug;1864(8):129618. doi:10.1016/j.bbagen.2020.129618.
27. Perli E, Pisano A, Pignataro MG, Campese AF, Pelullo M, Genovese I, de Turris V, Ghelli AM, Cerbelli B, Giordano C, Colotti G, Morea V, d'Amati G.
“Exogenous peptides are able to penetrate human cell and mitochondrial membranes, stabilize mitochondrial tRNA structures, and rescue severe mitochondrial defects.
FASEB J. 2020 Jun;34(6):7675-7686. doi: 10.1096/fj.201903270R.
28. Battista T, Colotti G, Ilari A, Fiorillo A.
“Targeting Trypanothione Reductase, a Key Enzyme in the Redox Trypanosomatid Metabolism, to Develop New Drugs against Leishmaniasis and Trypanosomiases”.
Molecules. 2020 Apr 21;25(8):1924. doi: 10.3390/molecules25081924.
29. Colotti G*, Rinaldi T.
“The central role of gut microbiota in drug metabolism and personalized medicine”.
Future Med Chem. 2020 May 29. doi: 10.4155/fmc-2020-0023.
30. Turcano L, Battista T, De Haro ET, Missineo A, Alli C, Paonessa G, Colotti G, Harper S, Fiorillo A, Ilari A, Bresciani A.
“Spiro-containing derivatives show antiparasitic activity against Trypanosoma brucei through inhibition of the trypanothione reductase enzyme”.
PLoS Negl Trop Dis. 2020 May 21;14(5):e0008339. doi: 10.1371/journal.pntd.0008339.
31. Mascia A, Cirafici AM, Bongiovanni A, Colotti G, Lacerra G, Di Carlo M, Digilio FA, Liguori GL, Lanati A, Kisslinger A.
“A failure mode and effect analysis (FMEA)-based approach for risk assessment of scientific processes in non-regulated research laboratories
Accreditation And Quality Assurance. 2020. doi: 10.1007/s00769-020-01441-9.
32. Genovese I, Giamogante F, Barazzuol L, Battista T, Fiorillo A, Vicario M, D'Alessandro G, Cipriani R, Limatola C, Rossi D, Sorrentino V, Poser E, Mosca L, Squitieri F, Perluigi M, Arena A, van Petegem F, Tito C, Fazi F, Giorgi C, Calì T, Ilari A, Colotti G*.
“Sorcin is an early marker of neurodegeneration, Ca2+ dysregulation and endoplasmic
reticulum stress associated to neurodegenerative diseases.”
Cell Death Dis. 2020 Oct 15;11(10):861. doi: 10.1038/s41419-020-03063-y.
33. Flego M, Colotti G, Ascione A, Dupuis ML, Petrucci E, Riccioni R, Andreotti M, Raggi C, Boe A, Barca S, Gellini M, Vella S, Mallano A.
“Isolation and preliminary characterization of a human 'phage display'-derived antibody against neural adhesion molecule-1 antigen interfering with fibroblast growth factor receptor-1 binding.”
Hum Antibodies. 2020 Oct 23. doi: 10.3233/HAB-200431.
34. Mosca L, Ilari A, Fazi F, Assaraf YG, Colotti G*.
“Taxanes in cancer treatment: Activity, chemoresistance and its overcoming.”
Drug Resist Updat. 2021 Jan;54:100742. doi: 10.1016/j.drup.2020.100742.
35. Chiarini V, Fiorillo A, Camerini S, Crescenzi M, Nakamura S, Battista T, Guidoni L, Colotti G*, Ilari A.
“Structural basis of ubiquitination mediated by protein splicing in early Eukarya.”
Biochim Biophys Acta Gen Subj. 2021 May;1865(5):129844. doi: 10.1016/j.bbagen.2021.129844.
36. Battista T, Pascarella G, Staid DS, Colotti G, Rosati J, Fiorillo A, Casamassa A, Vescovi AL, Giabbai B, Semrau MS, Fanelli S, Storici P, Squitieri F, Morea V, Ilari A.
“Known Drugs Identified by Structure-Based Virtual Screening Are Able to Bind Sigma-1 Receptor and Increase Growth of Huntington Disease Patient-Derived Cells.”
Int J Mol Sci. 2021 Jan 28;22(3):1293. doi: 10.3390/ijms22031293.
37. Colotti G, Failla CM, Lacal PM, Ungarelli M, Ruffini F, Di Micco P, Morea V.
“Neuropilin-1 is required for endothelial cell adhesion to soluble vascular endothelial growth factor receptor 1”.
FEBS Journal, 2022, 15(1), 183-198. doi:10.1111/febs.16119.
38. Fiorillo A, Morea V, Colotti G, Ilari A.
“Huntingtin Ubiquitination Mechanisms and Novel Possible Therapies to Decrease the Toxic Effects of Mutated Huntingtin”.
J. Pers. Med. 2021, 11(12), 1309; doi:10.3390/jpm11121309
39. Valentini E, DAguanno S, Di Martile M, Montesano C, Ferraresi V, Patsilinakos A, Sabatino M, Antonini L, Valente S, Mai A, Colotti G, Ragno R, Trisciuoglio D, Del
Bufalo D.
“Targeting the anti-apoptotic Bcl-2 family proteins: machine learning virtual screening and biological evaluation of new small molecules”.
Theranostics 2022, 12(5), 2427-2444; doi:10.7150/thno.64233.
40. Di Risola D, Ricci D, Marrocco I, Giamogante F, Grieco M, Francioso A, Vasco-Vidal A, Mancini P, Colotti G*, Mosca L, Altieri F.
“ERp57 chaperon protein protects neuronal cells from Aβ-induced toxicity”.
J Neurochem. 2022; 162(4):322-336. doi: 10.1111/jnc.15655.
41. Fiorillo A, Colotti G, Exertier C, Liuzzi A, Seghetti F, Salerno A, Caciolla J, Ilari A.
"Innovative Approach for a Classic Target: Fragment Screening on Trypanothione Reductase Reveals New Opportunities for Drug Design”.
Front Mol Biosci. 2022; 9:900882. doi: 10.3389/fmolb.2022.900882.
42. Battista T, Federico S, Brogi S, Pozzetti L, Khan T, Butini S, Ramunno A, Fiorentino E, Orsini S, Di Muccio T, Fiorillo A, Exertier C, Di Risola D, Colotti G*, Gemma S, Ilari A, Campiani G.
“Optimization of Potent and Specific Trypanothione Reductase Inhibitors: A Structure Based Drug Discovery Approach”.
ACS Infect Dis. 2022; 8(8):1687-1699. doi: 10.1021/acsinfecdis.2c00325.
43. Tramonti A, Ghatge MS, Babor JT, Musayev FN, di Salvo ML, Barile A, Colotti G, Giorgi A, Paredes SD, Donkor AK, Al Mughram MH, de Crécy-Lagard V, Safo MK, Contestabile R.
“Characterization of the Escherichia coli pyridoxal 5'-phosphate homeostasis protein (YggS): Role of lysine residues in PLP binding and protein stability”.
Protein Sci. 2022; 31(11):e4471. doi: 10.1002/pro.4471.
44. Madia VN, Ialongo D, Patacchini E, Exertier C, Antonelli L, Colotti G, Messore A, Tudino V, Saccoliti F, Scipione L, Ilari A, Costi R, Di Santo R.
“Inhibition of Leishmania infantum Trypanothione Reductase by New Aminopropanone Derivatives Interacting with the NADPH Binding Site”.
Molecules. 2023; 28(1):338. doi: 10.3390/molecules28010338.
45. Pascarella G, Antonelli L, Narzi D, Battista T, Fiorillo A, Colotti G, Guidoni L, Morea V, Ilari A.
“Investigation of the Entry Pathway and Molecular Nature of σ1 Receptor Ligands”.
Int J Mol Sci. 2023 Mar 28;24(7):6367. doi: 10.3390/ijms24076367.
46. Zwergel C, Aventaggiato M, Garbo S, Di Bello E, Fassari B, Noce B, Castiello C, Lambona C, Barreca F, Rotili D, Fioravanti R, Schmalz T, Weyand M, Niedermeier A, Tripodi M, Colotti G, Steegborn C, Battistelli C, Tafani M, Valente S, Mai A.
"Novel 1,4-Dihydropyridines as Specific Binders and Activators of SIRT3 Impair Cell Viability and Clonogenicity, and Downregulate Hypoxia-Induced Targets in Cancer Cells"
Journal of Medicinal Chemistry 2023, 66(14): 9622-9641. doi: 10.1021/acs.jmedchem.3c00337.
47. Tito C, Genovese I, Giamogante F, Benedetti A, Miglietta S, Barazzuol L, Cristiano L, Iaiza A, Carolini S, De Angelis L, Masciarelli S, Nottola SA, Familiari G, Petrozza V, Lauriola M, Tamagnone L, Ilari A, Calì T, Valdivia HH, Valdivia CR, Colotti G*, Fazi F.
“Sorcin promotes migration in cancer and regulates the EGF-dependent EGFR signaling Pathways”.
Cellular and Molecular Life Sciences 2023;80(8):202. doi: 10.1007/s00018-023-04850-4
48. Valentini E, Di Martile M, Brignone M, Di Caprio M, Manni I, Chiappa M, Sergio I, Chiacchiarini M, Bazzichetto C, Conciatori F, D'Aguanno S, D'Angelo C, Ragno R, Russillo M, Colotti G, Felli M, Damia G, Del Bufalo D, Marchesi F, Bellone M, Dal Piaz F.
"Bcl-2 family inhibitors sensitize human cancer models to therapy".
Cell Death and Disease, 2023; 14(7):441. doi: 10.1038/s41419-023-05963-1.
49. Mattioli R, Ilari A, Colotti B, Mosca L, Fazi F, Colotti G*
" Doxorubicin and other anthracyclines in cancers: activity, chemoresistance and its overcoming".
Molecular Aspects of Medicine, 2023; 93:101205. doi:10.1016/j.mam.2023.101205
50: Fracasso G, Falvo E, Tisci G, Sala G, Colotti G, Cingarlini S, Tito C, Bibbo S, Frusteri C, Tremante E, Giordani E, Giacomini P, Ceci P.
Widespread in vivo efficacy of The-0504: A conditionally-activatable nanoferritin for tumor-agnostic targeting of CD71-expressing cancers.
Heliyon. 2023 Oct 6;9(10):e20770. doi: 10.1016/j.heliyon.2023.e20770.